Highly Depressed Men Helped More by Nicotine Patch Than Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

BETHESDA, Md--A surprising finding of a smoking cessation study using behavioral therapy is that highly depressed men, but not highly depressed women, must also have nicotine replacement therapy to keep from relapsing, Paul M. Cinciripini, PhD, said at a symposium on tobacco addiction sponsored by ASCO and the NCI.

BETHESDA, Md--A surprising finding of a smoking cessation studyusing behavioral therapy is that highly depressed men, but nothighly depressed women, must also have nicotine replacement therapyto keep from relapsing, Paul M. Cinciripini, PhD, said at a symposiumon tobacco addiction sponsored by ASCO and the NCI.

In this study of 120 smokers randomized to receive either behavioraltherapy alone or behavioral therapy plus the nicotine patch, smokerswere subdivided at randomization into high depression or low depressioncategories based on their initial score on the Profile of MoodStates (POMS) depression scale.

Dr. Cinciripini, associate professor of behavioral science, theUniversity of Texas M.D. Anderson Cancer Center, described thetherapy used in the study as "9 weeks of highly structured,highly interactive cognitive behavioral group counseling, fairlyheavy-duty behavioral intervention, and relapse prevention."

The study produced three major results: (1) Smokers who got thepatch did better at quitting than those who did not. (2) Smokersin the low-depression group did better than those with high depression.(3) When looking only at the high-depression group, the patchhelped the men more so than the women.

High-depressed female smokers did equally well if they got thecombination therapy or behavioral therapy alone, both at the endof treatment and at 6 months. In contrast, he said, "high-depressedmales had about a zero chance of being abstinent at 6 months ifthey did not receive the patch." Thus, he said, it appearsthat for highly depressed women, behavioral therapy may be "fundamentallyimportant."

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content